메뉴 건너뛰기




Volumn 4, Issue 1, 2009, Pages

No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - A pilot study

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ADEFOVIR DIPIVOXIL; APOMORPHINE; BOSENTAN; DESLORATADINE; EFALIZUMAB; EMTRICITABINE; ETIRACETAM; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; IMATINIB; KINZALKOMB; NITISINONE; ORPHAN DRUG; OXYBATE SODIUM; OXYBUTYNIN; PREGABALIN; UNCLASSIFIED DRUG; WILZIN; ZINC ACETATE;

EID: 75149126210     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-4-27     Document Type: Article
Times cited : (16)

References (10)
  • 2
    • 27644486590 scopus 로고    scopus 로고
    • Orphan drugs and the NHS: Should we value rarity?
    • 10.1136/bmj.331.7523.1016. 16254305
    • Orphan drugs and the NHS: should we value rarity? C McCabe K Claxton A Tsuchiya, BMJ 2005 331 1016 1019 10.1136/bmj.331.7523.1016 16254305
    • (2005) BMJ , vol.331 , pp. 1016-1019
    • McCabe, C.1    Claxton, K.2    Tsuchiya, A.3
  • 3
    • 75149148229 scopus 로고    scopus 로고
    • Availability of orphan medicinal products in the EU [abstract]
    • Availability of orphan medicinal products in the EU [abstract]. F Bignami Y le Cam F Faurisson F Houez, Eur J PublicHealth 2004 14 suppl 1 81
    • (2004) Eur J PublicHealth , vol.14 , Issue.SUPPL 1 , pp. 81
    • Bignami, F.1    Le Cam, Y.2    Faurisson, F.3    Houez, F.4
  • 4
    • 84868360747 scopus 로고    scopus 로고
    • European Organisation for Rare Diseases (Eurordis) Accessed: December 2008
    • th Eurordis survey on orphan drug availability in Europe. European Organisation for Rare Diseases (Eurordis), 2007 http://www.eurordis. org/article.php3?id-article=1013 Accessed: December 2008
    • (2007) th Eurordis Survey on Orphan Drug Availability in Europe
  • 5
    • 75149139119 scopus 로고    scopus 로고
    • About the ATC/DDD system
    • WHO Collaborating Centre for Drug Statistics
    • About the ATC/DDD system. WHO Collaborating Centre for Drug Statistics, Methodology http://www.whocc.no/
    • Methodology
  • 6
    • 33751242048 scopus 로고    scopus 로고
    • Between-country variation in the utilization of antihypertensive agents: Guidelines and clinical practice
    • 10.1038/sj.jhh.1002089. 16988753
    • Between-country variation in the utilization of antihypertensive agents: Guidelines and clinical practice. P Stolk BL Van Wijk HG Leufkens ER Heerdink, J Hum Hypertens 2006 20 917 922 10.1038/sj.jhh.1002089 16988753
    • (2006) J Hum Hypertens , vol.20 , pp. 917-922
    • Stolk, P.1    Van Wijk, B.L.2    Leufkens, H.G.3    Heerdink, E.R.4
  • 7
    • 17144414136 scopus 로고    scopus 로고
    • Therapeutic innovation in the European Union: Analysis of the drugs approved by the EMEA between 1995 and 2003
    • 10.1111/j.1365-2125.2004.02320.x
    • Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003. D Motola F De Ponti P Rossi N Martini N Montanaro, Br J ClinPharmacol 2004 59 475 478 10.1111/j.1365-2125. 2004.02320.x
    • (2004) Br J ClinPharmacol , vol.59 , pp. 475-478
    • Motola, D.1    De Ponti, F.2    Rossi, P.3    Martini, N.4    Montanaro, N.5
  • 8
    • 75149116980 scopus 로고    scopus 로고
    • Centro Regionale di Valutazione e Informazione sui Farmacia [updated 2005]: Accessed December 2008
    • Therapeutic innovation. Centro Regionale di Valutazione e Informazione sui Farmacia, http://www.crevif.it/innovation/index.htm [updated 2005]: Accessed December 2008
    • Therapeutic Innovation
  • 9
    • 79960652527 scopus 로고    scopus 로고
    • No 141/2000 adopted on 16 December 1999 (OJ No L 19, 22.1.2000)
    • Regulation (EC). No 141/2000 adopted on 16 December 1999 (OJ No L 19, 22.1.2000)
    • Regulation (EC)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.